This small open-label trial (n=8) will test the safety of two doses of the ayahuasca brew containing DMT (1.0mg to 1.4mg/kg). The trial is sponsored by Psychae and is done in collaboration with St. Vincent’s Hospital in Melbourne Australia.
Topic Healthy Subjects
Compound Ayahuasca
Country Australia
Visit trial
Status
Not yet recruiting
Results Published
No
Start date
05 November 2022
End date
21 April 2023
Chance of happening
100%
Phase
Phase I
Design
Open
Type
Interventional
Generation
First
Participants
8
Sex
All
Age
25- 70
Therapy
No
Trial Details
Initially, two orally administered DMT (1.0mg/kg) and harmala alkaloid formulations (4mg/kg) will be provided in separate single-dose sessions to 8 healthy volunteers (with prior experience of these substances). After this data is collected, an interim assessment of the psychedelic effect and safety parameters will occur, with one of the formulations being chosen for the next dosage level. The amount given to the 8 participants will be increased to: DMT (1.4mg/kg) and harmala alkaloids (5.6mg/kg). Participants will be given both formulations in a cross-over design (16 psychedelic sessions in total), with a 2-week washout between treatments. Initial treatment group assignment will be randomised. Post-monitoring will occur to assess the more chronic effects of the treatments.NCT Number
Sponsors & Collaborators
Psychae InstitutePsychae Institute is dedicated to developing novel psychedelic therapies as registered medical treatments for mental disorders and other diseases, as well as supporting psychological wellbeing.